Rodrigo Meza-Romero

Rodrigo Meza-Romero

Auto-generated profile, based on publicly available information

Rodrigo Meza-Romero

Department of Dermatology Escuela de Medicina Pontificia Universidad Catolica de Chile Santiago Chile

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2019 in Clinical, Cosmetic and Investigational Dermatology
Verified
Journal Article
Open access
PDF file
RMRodrigo Meza-Romero
Rodrigo Meza-Romero
Cristian Navarrete-DechentCristian Navarrete-Dechent
Cristian Navarrete-Dechent
CDCamila Downey
Camila Downey
Molluscum contagiosum (MC) is a self-limited infectious dermatosis, frequent in pediatric population, sexually active adults, and immunocompromised individuals. It is caused by molluscum contagiosum virus (MCV) which is a virus of the Poxviridae family. MCV is transmitted mainly by direct contact with infected skin, which can be sexual, non-sexual, or autoinoculation. Clinically, MC presents as firm rounded papules, pink or skin-colored, with a shiny and umbilicated surface. The duration of the lesions is variable, but in most cases, they are self-limited in a period of 6–9 months. The skin lesions may vary in size, shape, and location, which is more frequent in immunosuppressed patients, and could present complications such as eczema and bacterial superinfection. The diagnosis is based on clinical findings. A useful clinical tool is dermoscopy. If the diagnostic doubt persists, confocal microscopy or skin biopsy could be performed. The need for active treatment for MC is controversial; however, there is a consensus that it should be indicated in cases of extensive disease, associated with complications or aesthetic complaints. There are several treatment modalities which include mechanical, chemical, immunomodulatory, and antivirals. The objective of this article is to review the current evidence in etiology, clinical manifestations, diagnosis, and management alternatives of MC.

22 November 2020 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Closed access
PDF file
CMCamila Muñoz‐López
Camila Muñoz‐López
CRCristian Ramírez‐Cornejo
Cristian Ramírez‐Cornejo
MMMichael A. Marchetti
Michael A. Marchetti
SHSeung Seog Han
Seung Seog Han
PBPablo Del Barrio‐Díaz
Pablo Del Barrio‐Díaz
Cristian Navarrete-DechentCristian Navarrete-Dechent
Cristian Navarrete-Dechent

1 January 2018 in Journal of the American Academy of Dermatology
Verified
Journal Article
Closed access
XWXimena Wortsman
Ximena Wortsman
PBPablo Del Barrio-Díaz
Pablo Del Barrio-Díaz
RMRodrigo Meza-Romero
Rodrigo Meza-Romero
CPChristine Poehls-Risco
Christine Poehls-Risco
CVCristián Vera-Kellet
Cristián Vera-Kellet

1 December 2021 in European Journal Of Dermatology
Verified
Journal Article
Open access
PDF file
CVCristián Vera-Kellet
Cristián Vera-Kellet
RMRodrigo Meza-Romero
Rodrigo Meza-Romero
CMCatherina Moll-Manzur
Catherina Moll-Manzur
CRCristian Ramírez-Cornejo
Cristian Ramírez-Cornejo
XWXimena Wortsman
Ximena Wortsman
The effectiveness of methotrexate (MTX), a first-line treatment for localised scleroderma (morphea), has not been assessed using colour Doppler ultrasonography (CDU). We aimed to ultrasonographically monitor disease activity in patients with morphea treated with MTX, assessing its effectiveness using an Ultrasound Morphea Activity Score (US-MAS). A retrospective cohort of 22 patients was studied between July 2014 and July 2019. The morphea of each patient, treated with MTX, was confirmed by histology and all patients had at least two CDU examinations. The US-MAS is based on published ultrasound signs of disease activity validated by histology. A weight-adjusted average MTX dose (mg/kg/wk) was used to standardize dosage, weight, and time between CDU examinations. The difference in US-MAS between two CDU examinations was determined. Statistical analyses included Wilcoxon and Fisher exact tests, the Spearman correlation coefficient, and risk ratios with 95% confidence intervals. To create two groups, we determined the median of the sample as the cut-off point for MTX dose (0.265 mg/kg/week). Significance was set at p≤0.05; Results: In all cases, CDU examinations showed subclinical signs of activity beyond the visible lesional borders, either in the same or adjacent corporal segments. A negative correlation was found between the change in US-MAS and MTX dose (Spearman coefficient, -0.45; p = 0.035). The group dosed at ≥0.265 mg/kg/wk showed a non-significant change in US-MAS (2-point decrease). No case became inactive. MTX is a treatment with a low effectiveness for morphea, causing only slight decreases in ultrasound activity at higher doses.

29 March 2017 in Medwave
Verified
Journal Article
Open access
RMRodrigo Meza
Rodrigo Meza
JPJavier Peña
Javier Peña
KGKaren García
Karen García
OCOscar Corsi
Oscar Corsi
GRGabriel Rada
Gabriel Rada
Resumen\ud En el último tiempo, se han descrito diversos beneficios con el uso de cannabinoides en diferentes situaciones clínicas. Dentro de ellas se ha planteado un posible efecto en el control de la esclerosis múltiple, pero la real utilidad clínica es tema de debate. Para responder a esta pregunta utilizamos la base de datos Epistemonikos, la cual es mantenida mediante búsquedas en múltiples bases de datos. Identificamos 25 revisiones sistemáticas que en conjunto incluyen 35 estudios que responden la pregunta de interés, entre ellos 26 estudios aleatorizados. Extrajimos los datos, realizamos un metanálisis y preparamos una tabla de resumen de los resultados utilizando el método GRADE. Concluimos que el uso de cannabinoides en esclerosis múltiple no reduce la espasticidad ni el dolor, y probablemente se asocia a efectos adversos frecuentes

20 March 2020 in The International Journal of Artificial Organs
Verified
Journal Article
Closed access
PDF file
RRRocío X Rodríguez
Rocío X Rodríguez
LVLuis A Villarroel
Luis A Villarroel
RMRodrigo A Meza
Rodrigo A Meza
JPJavier I Peña
Javier I Peña
CMClaudia Musalem
Claudia Musalem
SUSoledad Urzúa
Soledad Urzúa
Objectives: To describe risk factors for acquired infection during neonatal extracorporeal membrane oxygenation and to examine the predictive value of inflammatory markers in the diagnosis of infection. Methods: A retrospective study was conducted with data for patients under 30 days supported with extracorporeal membrane oxygenation from 2003 to April 2016, in a neonatal intensive care unit. Results: Our study included 160 neonatal patients, the average age of connection was 8.5 days and the duration of extracorporeal membrane oxygenation support was 9.7 days. The incidence of confirmed infection was 23%. Patients with confirmed infection present more frequently: vaginal delivery, lower birth weight, female sex, diagnosis of congenital diaphragmatic hernia, and longer duration of extracorporeal membrane oxygenation. When comparing the group of patients with confirmed infection and suspicion of infection, there were no significant differences in the inflammatory markers. When calculating the slope for each one, the difference in white blood cell count slope 72 h before the infection is significant; in patients with confirmed infection, the count of white blood cell increases (slope: 0.25), versus the group of patients with suspected infection in whom the count decreases (slope: −0.39). No differences were found in other variables. Conclusion: Our study describes that the factors that increase the risk of infection are lower birth weight, vaginal birth, duration of extracorporeal membrane oxygenation, and a positive trend of white blood cell 72 h prior to infection/suspicion. Further studies are necessary to include or definitively rule out the use of these factors and the biomarkers as predictors of infection in neonatal patients supported with extracorporeal membrane oxygenation.